(VIANEWS) – Halozyme Therapeutics (HALO), Towers Watson & Co (TW), Crane Company (CR) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Halozyme Therapeutics (HALO)
19.8% sales growth and 261.68% return on equity
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; NOCDURNA, a sublingual tablet to treat nocturia due to nocturnal polyuria; TLANDO, an oral formulation for testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of multiple blood cancer; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergy and immunology; Sumatriptan injection for migraines; exenatide and teriparatide injections; Makena, a progestin drug to reduce the risk of preterm birth; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Halozyme Therapeutics has a trailing twelve months EPS of $2.41.
PE Ratio
Halozyme Therapeutics has a trailing twelve months price to earnings ratio of 18.69. Meaning, the purchaser of the share is investing $18.69 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 261.68%.
Yearly Top and Bottom Value
Halozyme Therapeutics’s stock is valued at $45.05 at 11:22 EST, under its 52-week high of $46.16 and way above its 52-week low of $32.78.
Volume
Today’s last reported volume for Halozyme Therapeutics is 1007450 which is 4.89% above its average volume of 960477.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 1.4% and 36%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 20.8%, now sitting on 862.99M for the twelve trailing months.
Previous days news about Halozyme Therapeutics(HALO)
- According to Zacks on Friday, 14 June, "Another stock from the same industry, Halozyme Therapeutics (HALO Quick QuoteHALO – Free Report) , has gained 9.3% over the past month. "
2. Towers Watson & Co (TW)
18.5% sales growth and 7.89% return on equity
Tradeweb Markets Inc., together with its subsidiaries, builds and operates electronic marketplaces worldwide. The company's marketplaces facilitate trading in a range of asset classes, including rates, credit, money markets, and equities. It offers pre-trade data and analytics, trade execution, and trade processing, as well as post-trade data, analytics, and reporting services. The company provides flexible order and trading systems to institutional investors. It also offers a range of electronic, voice, and hybrid platforms to dealers and financial institutions on electronic or hybrid markets with Dealerweb platform; and trading solutions for financial advisory firms and traders with Tradeweb Direct platform. The company serves in the institutional, wholesale, and retail client sectors. Its customers include asset managers, hedge funds, insurance companies, central banks, banks and dealers, proprietary trading firms, retail brokerage and financial advisory firms, and regional dealers. The company was founded in 1996 and is headquartered in New York, New York. Tradeweb Markets Inc. operates as a subsidiary of Refinitiv Parent Limited.
Earnings Per Share
As for profitability, Towers Watson & Co has a trailing twelve months EPS of $1.71.
PE Ratio
Towers Watson & Co has a trailing twelve months price to earnings ratio of 59.73. Meaning, the purchaser of the share is investing $59.73 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.89%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 23.8%, now sitting on 1.42B for the twelve trailing months.
Yearly Top and Bottom Value
Towers Watson & Co’s stock is valued at $102.13 at 11:22 EST, way below its 52-week high of $114.07 and way higher than its 52-week low of $64.83.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Jun 3, 2024, the estimated forward annual dividend rate is 0.4 and the estimated forward annual dividend yield is 0.38%.
Moving Average
Towers Watson & Co’s worth is under its 50-day moving average of $106.09 and above its 200-day moving average of $96.55.
3. Crane Company (CR)
9.9% sales growth and 12.42% return on equity
Crane Co. manufactures and sells engineered industrial products in the United States, Canada, the United Kingdom, Continental Europe, and internationally. The company's Fluid Handling segment offers on/off valves and related products for the chemical, oil and gas, power, and general industrial end markets; valves and related products for the non-residential construction, general industrial, and municipal markets; fluid control instrumentation and sampling solutions; and pumps and related products for water and wastewater applications in industrial, municipal, commercial, and military markets. This segment sells its products under the Crane, Saunders, Jenkins, Pacific, Xomox, Krombach, DEPA, ELRO, REVO, Flowseal, Centerline, Resistoflex, Duochek, Barksdale, Westlock, WTA, HOKE, DOPAK, Stockham, Wask, Viking Johnson, IAT, Hattersley, NABIC, Sperryn, Wade, Deming, Weinman, Burks, and Barnes brands. Its Payment & Merchandising Technologies segment provides technology payment acceptance and dispensing products to original equipment manufacturers and for vertical markets; currency handling and processing systems, cash and cashless payment and merchandising solutions, equipment service solutions, and connected managed service solutions. The company's Aerospace & Electronics segment offers original equipment and aftermarket parts under the Hydro-Aire, ELDEC, Lear Romec, P.L. Porter, Keltec, Interpoint, Signal Technology, Merrimac Industries, and Polyflon brands to commercial and military aerospace, and defense and space markets. Its Engineered Materials segment provides fiberglass-reinforced plastic panels and coils primarily for use in the manufacturing of recreational vehicles, truck bodies, and trailers, as well as used in commercial and industrial building construction. Crane Co. was founded in 1855 and is based in Stamford, Connecticut.
Earnings Per Share
As for profitability, Crane Company has a trailing twelve months EPS of $3.67.
PE Ratio
Crane Company has a trailing twelve months price to earnings ratio of 38.07. Meaning, the purchaser of the share is investing $38.07 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.42%.
4. Assurant (AIZ)
8% sales growth and 16.43% return on equity
Assurant, Inc., together with its subsidiaries, provides lifestyle and housing solutions that support, protect, and connect consumer purchases in North America, Latin America, Europe, and the Asia Pacific. The company operates through three segments: Global Lifestyle, Global Housing, and Global Preneed. The Global Lifestyle segment provides mobile device protection products and services, and extended service contracts for consumer electronics and appliances, as well as assistance services; vehicle protection and related services; and credit and other insurance services. The Global Housing segment offers lender-placed homeowners insurance, manufactured housing, and flood insurance; and renters insurance and related products, as well as voluntary manufactured housing insurance, homeowners insurance, and other specialty products. The Global Preneed segment provides pre-funded funeral insurance, final need insurance, and related services. The company was formerly known as Fortis, Inc. and changed its name to Assurant, Inc. in February 2004. Assurant, Inc. was founded in 1892 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, Assurant has a trailing twelve months EPS of $14.29.
PE Ratio
Assurant has a trailing twelve months price to earnings ratio of 11.76. Meaning, the purchaser of the share is investing $11.76 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.43%.
Sales Growth
Assurant’s sales growth is 5.9% for the current quarter and 8% for the next.
Volume
Today’s last reported volume for Assurant is 265654 which is 22.91% below its average volume of 344628.
Moving Average
Assurant’s worth is below its 50-day moving average of $174.27 and higher than its 200-day moving average of $165.56.
Revenue Growth
Year-on-year quarterly revenue growth grew by 9%, now sitting on 11.37B for the twelve trailing months.
5. Franklin Resources (BEN)
8% sales growth and 7.75% return on equity
Franklin Resources, Inc. is a publicly owned asset management holding company. Through its subsidiaries, the firm provides its services to individuals, institutions, pension plans, trusts, and partnerships. It launches equity, fixed income, balanced, and multi-asset mutual funds through its subsidiaries. The firm invests in the public equity, fixed income, and alternative markets. Franklin Resources, Inc. was founded in 1947 and is based in San Mateo, California with an additional office in Hyderabad, India.
Earnings Per Share
As for profitability, Franklin Resources has a trailing twelve months EPS of $1.73.
PE Ratio
Franklin Resources has a trailing twelve months price to earnings ratio of 12.69. Meaning, the purchaser of the share is investing $12.69 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.75%.
6. UMB Financial Corporation (UMBF)
6.7% sales growth and 12.33% return on equity
UMB Financial Corporation operates as the bank holding company for the UMB Bank that provides various banking and other financial services. The Commercial Banking segment provides commercial loans and credit cards; commercial real estate financing; letters of credit; loan syndication, and consultative services; various business solutions including asset-based lending, accounts receivable financing, mezzanine debt, and minority equity investments; and treasury management services, such as depository services, account reconciliation, cash management tools, accounts payable and receivable solutions, electronic fund transfer and automated payments, controlled disbursements, lockbox services, and remote deposit capture services. The Institutional Banking segment offers fund administration and accounting, investor services and transfer agency, marketing and distribution, custody, alternative investment services, fixed income sales, trading and underwriting, and corporate trust and escrow services, as well as institutional custody services. This segment also provides healthcare payment solutions comprising custodial services for health savings accounts and private label, multipurpose debit cards to insurance carriers, third-party administrators, software companies, employers, and financial institutions. The Personal Banking segment offers deposit accounts, retail credit cards, private banking, installment loans, home equity lines of credit, residential mortgages, and small business loans, as well as internet banking, ATM network, private banking, brokerage and insurance services, and advisory and trust services. It operates through a network of branches and offices in the states of Missouri, Kansas, Colorado, Illinois, Oklahoma, Texas, Arizona, Nebraska, Iowa, Pennsylvania, South Dakota, Indiana, Utah, Minnesota, California, and Wisconsin. UMB Financial Corporation was founded in 1913 and is headquartered in Kansas City, Missouri.
Earnings Per Share
As for profitability, UMB Financial Corporation has a trailing twelve months EPS of $7.53.
PE Ratio
UMB Financial Corporation has a trailing twelve months price to earnings ratio of 10.76. Meaning, the purchaser of the share is investing $10.76 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.33%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 7.6% and 0.5%, respectively.
Sales Growth
UMB Financial Corporation’s sales growth for the next quarter is 6.7%.
